Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure

Cytokinetics Incorporated CYTK announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF).
Data were presented at the American College of Cardiology’s Annual Scientific Session.
Last year, the heart drug technically met its primary endpoint but missed a key secondary endpoint reduction in cardiovascular death.
In a posthoc analysis, Cytokinetics separated patients from the Phase 3 GALACTIC-HF study into four quartiles based on ejection fraction (EF), which measured how well the left ventricle pumps blood with each heartbeat.
Patients in the lower two quartiles, those with an EF of 22% or lower and between 29% to 32%, saw a 15% and 17% relative risk reduction of heart failure events and cardiovascular death combined.
No difference was seen in the upper two quartiles.
When considering heart failure events alone, the relative risk reduction for the lower two quartiles was 19% and 17%, respectively, with no difference seen in the upper two quartiles.
Omecamtiv mecarbil works by targeting myosin, a protein that converts chemical energy into mechanical force in the heart.
In October, Cytokinetics announced the drug reduced the odds of hospitalization or other urgent care for heart failure by 8%.
However, even the subgroups with lower EF missed the secondary endpoint of a reduction in cardiovascular death.
Cytokinetics says it’s planning on submitting a marketing application for the candidate in the second half of this year.
Price Action: CYTK shares are up 0.50% at $26.06 during the market session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga